Hidradenitis Suppurativa (HS) remains one of the most challenging inflammatory skin diseases to diagnose, treat, and manage long term. While therapeutic innovation in dermatology continues to accelerate, HS still faces significant unmet need, including delayed diagnosis, irreversible tissue damage, limited biomarkers, and comparatively slow translational progress. This workshop

will explore how earlier intervention strategies and emerging therapeutic approaches could shift HS management beyond reactive symptom control toward improving long-term outcomes and potentially modifying disease progression.

Attendees will gain insight into the evolving HS treatment landscape, the scientific and clinical barriers slowing progress, and what is needed to strengthen translational development in this underserved area of inflammatory disease.

Key Questions to be Addressed:

• How can earlier intervention influence long-term disease progression and tissue damage in HS?
• What evidence is needed to support earlier use of advanced therapies in HS care pathways?
• Why has HS seen comparatively limited preclinical and translational advancement compared with other inflammatory diseases?
• What lessons can HS learn from earlier biologic intervention strategies used in psoriasis, atopic dermatitis, and other chronic inflammatory conditions?
• How can the field move beyond symptom management toward disease modification and improved quality of life for patients living with HS?